Baseline characteristics of patients used in test and validation cohorts.

<p>ND = not defined, NA = not available</p><p>Baseline characteristics of healthy donors (HD), newly diagnosed multiple myeloma (MM) patients and patients with extramedullary myeloma (EM) used in a test and validation phase of the study. P values show differences in clinical parameters between studied groups, significant differences are marked in bold.</p

MicroRNA expression pattern in extramedullary myeloma (EM), multiple myeloma (MM) patients and healthy donors (HD).

<p>Hierarchical clustergram discriminating EM serum samples from A) MM, yellow color indicates EM serum samples, light blue MM serum samples, <i>p</i><0.05. B) HD, yellow color indicates EM serum samples, dark blue indicates HD serum samples, <i>p</i><0.05. Differential expression of miRNA is shown by the intensity of red (up-regulation) <i>versus</i> green (down-regulation).</p

Level of miR-130a in CD138+ bone marrow plasma cells and tumor plasma cells.

<p>Level of miR-130a normalized to RNU48 in bone marrow plasma cells (BMPCs) and tumor plasma cells of multiple myeloma (MM) patients and patients with extramedullary disease (EM).</p

Correlation of serum miR-130a levels with clinically important biochemical parameters.

<p>Data are presented as coefficients of correlation. Statistically significant correlations are marked in bold and italics.</p

MiRNA levels in a validation cohort of patients.

<p>Data are presented as median of normalized miRNA expression and interquartile range. Mann-Whitney U test was used to compare the values. Fold change (FC) between extramedullary myeloma disease (EM) patients <i>versus</i> multiple myeloma (MM) patients and p values are presented. Significant values <i>p</i><0.05 are marked with bold and italics.</p

Receiver operating characteristic (ROC) analysis.

<p>ROC curves for miR-130a distinguishing <b>A)</b> extramedullary myeloma (EM) patients from healthy donors (HD) with area under the curve (AUC) = 0.856, <b>B)</b> EM patients from newly diagnosed multiple myeloma patients (MM new diagnosis) with AUC = 0.598 in a test cohort <b>C)</b> EM patients from MM patients (with PET/CT negative for EM) with AUC = 0.761 in a validation cohort.</p

MiRNA levels in a test cohort of patients.

<p>Data are presented as a median of normalized miRNA expression and interquartile range. Kruskal-Wallis test was used to compare the values. Fold change (FC) between extramedullary myeloma (EM) patients <i>versus</i> newly diagnosed multiple myeloma patients (EM/MM) and extramedullary myeloma patients <i>versus</i> healthy donors (EM/HD), and p values are presented. Significant values <i>p</i><0.05 are marked with bold and italics.</p